Dr. Reddy’s Shares Slip After Canada Non-Compliance Notice

Dr. Reddy’s Laboratories saw its share price fall almost 4% on Thursday, October 30, 2025, after the company said it had received a “Notice of Non-Compliance (NON)” from Canada’s Pharmaceutical Drugs Directorate.
The notice was linked to the company’s Abbreviated New Drug Submission (ANDS) for a generic version of Semaglutide injection, a medicine widely used for type 2 diabetes and obesity.

At around 12:36 pm IST, the stock was trading at ₹1,201.70, down from the previous close of ₹1,250.90, showing a 3.93% drop. The company confirmed it had received the notice and said it “continues to believe in the quality, safety, and comparability of its product.”
It added that it would keep working with the Canadian regulator to clarify the issues and is “determined to make Semaglutide available to patients in Canada and other markets as soon as possible,” once approvals are granted.

This is important because Semaglutide is seen as a big growth opportunity for Dr. Reddy’s. The original drug, used for both blood sugar control and weight management, is among the world’s most popular and high-demand medicines. Many companies are racing to launch generic versions to capture new markets.
So, a regulatory notice from Canada could delay the launch of Dr. Reddy’s version, meaning the company might miss out on early sales or have to spend extra time and resources to meet the required standards.

Market experts say this is not the end of the road for the drug, but it does create a delay risk. The NON means the company must provide more data or clarifications before approval.
Some brokerage reports suggest the approval timeline might move to March–June 2026, instead of the earlier expectation of late 2025.
For investors, this means the revenue boost from Semaglutide could now come later than planned.

Even so, Dr. Reddy’s stressed that it remains confident about the product and will continue pursuing regulatory clearance. This suggests that the opportunity is delayed, not lost. Once the product clears review, the company could still gain from the strong global demand for anti-obesity and diabetes drugs.

The sharp fall in share price shows that the market quickly reacted to the news. Investors are likely reassessing whether earlier expectations for Semaglutide were too high and how much this delay could affect earnings in the near term. However, for long-term investors, such dips can sometimes create buying opportunities if the company manages to resolve the issue quickly.

The event also serves as a reminder of regulatory risk in the pharma sector. Drug makers that export generics to international markets depend heavily on approvals from foreign regulators. A single delay or rejection can temporarily impact stock performance and sentiment.

Overall, the Canadian NON is a setback, but not a shutdown. Dr. Reddy’s strong record in developing high-quality generics and its ongoing communication with the authorities indicate that the issue is likely procedural or technical, rather than a major product flaw.
If the company manages to clear the regulator’s questions soon, the market reaction may stabilize and investor confidence could return.